Our history

Founded in 2014, aptaTargets was spun-out of Aptus Biotech, an aptamer technology platform. aptaTargets started a drug development program collaborating with the Complutense University and the Ramon y Cajal Hospital.

In 2019 and 2020, aptaTargets conducted the First-in-Human clinical trial in healthy volunteers (NCT04742062). A Phase Ib/IIa trial in acute ischemic stroke patients is currently in progress (APRIL study, NCT04734548), with the Phase Ib portion completed in June 2021.

aptaTargets raised a Series B round in 2020, from Inveready Asset Management and the CDTI (Centre for the Development of Industrial Technology), through the INNVIERTE program.

clinical-stage biopharmaceutical using aptamer technology for targeting acute indications.
(Lead-candidate) is a neuroprotective drug for acute ischemic stroke by targeting inflammation in the acute phase.
Targeting indications
where inflammation causes significant damage, including ischemic stroke, intracerebral hemorrhage, myocardial infarction, and multiple sclerosis.